Biologics Manufacturing Japan 2020
Home to the second-largest pharmaceutical market in the world, Japan has poised itself as one of the most lucrative biotech hubs in Asia and worldwide. Over recent years, the Japanese biologics market has opened its doors to both foreign companies entering the Japanese market and companies investing abroad. Japan’s biopharma sector has had a keen eye on alliance opportunities in markets beyond its borders and although the nature of its sector is a cautious one, its move towards transparency and international collaboration provides bountiful opportunities that both the domestic and international players stand to benefit from. The key drivers driving the growth of the biologics industry in Japan are the formation of numerous bio-clusters that house world-class universities with cutting-edge technologies and know-how, excellence in the implementation of automation technology, huge amounts of financial support for orphan drugs, tax breaks, and subsidies for new entrants in the market, the government’s push for the creation of technologies and services, and development of the supporting infrastructure. Factors hindering the growth of the biopharmaceutical industry mainly are from the bioprocessing side including high-manufacturing complexities, expensive purification processes and other challenges across the bioprocessing value chain.
The Inaugural Biologics Manufacturing Japan 2020, therefore, aims to provide a neutral platform to address the challenges faced in this sector including high costs incurred in the downstream purification of highly complex molecules, purification process development to maximize process economy, difficulties in process development, scale-up and technology transfer for biologics, reduction of Cost-of-Goods for large-scale manufacturing, insights into the regulatory perspective on common pitfalls in analytical and CMC studies, Single-Use Systems in USP & DSP and Cost-Benefit analysis of CMO outsourcing strategies
Key Entities in the Japanese Biologics space include Chugai Pharmaceutical, Kyowa Hakko Kirin, UMN
Pharma, Daiichi Sankyo, Asahi Glass Co., Astellas Pharma and Fujifilm Holdings Corp among others.
Biologics Manufacturing Japan will once again serve as the only bioprocessing focused platform in Japan for global partners and local stakeholders to leverage partnership opportunities, scientific innovation and manufacturing best practice case studies. This event will see the complete network of BIG Pharma, International Biopharma, Japanese Biopharma, Contract Manufacturing Organisations, Academic & Research Institutes, Regulatory Authorities, Solution Providers and Technocrats under one roof. If Japan is the country you are looking at for plentiful opportunities in the bio-manufacturing space, then Biologics Manufacturing Japan 2020 is where you have to be!
To become a speaker yourself, contact: Kashmiira Nayar, Conference Producer, T: +65 3109 0122, E: firstname.lastname@example.org
Hiroshi Murata Chugai Pharmaceuticals
Justin Prien Takeda Pharmaceutical
Palani Palaniappan Sarepta Therapeutics
Akiko Ishii Watabe National Institute of Health Sciences, MHLW
Kazuchika Furuishi Hitachi Chemical Co. Ltd
Shuichi Yamamoto Yamaguchi University Biomedical Engineering Center
Kenji Yoshida Regenerative and Cellular Medicine Kobe Center, Sumitomo Dainippon Pharma Co., Ltd,
Haruhiko Tsumura SanBio Co., Ltd
Gary Knapick Bristol-Myers Squibb
Masahiro Kino-oka Osaka University
Marie Zhu MabPlex USA Inc.
Yong Jick Kim Polus Inc.
Pei-Jun Chen Mycenax Biotech Inc.
Susumu Uchiyama Osaka University
Rui Sato Kajima Corporation
Nitin Naik Frost & Sullivan
Allen Ho JHL Biotech
Ko-chung Lin PharmaEssentia
Manabu Fukuzawa Ministry of Health, Labour and Welfare (MHLW)
Biologics Manufacturing Japan will provide commercial organizations with the opportunity to educate the market by raising brand awareness and positioning yourselves as leaders in the field. By maximizing face time with key profiles from biologics manufacturers from the Nordics region regulators and national health organizations all in a single location, you will enjoy the option of privately arranged meetings and consultations with selected potential clients.
eBook: Attendee List for Biologics Manufacturing Japan 2019
eBook: Expert Opinions on Japan's Bio-Manufacturing Successes.
eBook: Japan's Production Capabilities
eBook: Partnerships in Japanese Biopharma Industry
For any queries regarding venue or accommodation, please contact:
Si Hui Sim
Senior Operations Executive
T: +65 3109 0224